Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K7 | O14733 | 8/20 | 0.42 |
| ▸ | KDR | P35968 | 10/20 | 0.40 |
| ▸ | TNNI3K | Q59H18 | 3/20 | 0.38 |
| ▸ | BRAF | P15056 | 2/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | TDP2 | O95551 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5439121 | 0.87 | MAP2K7 (0.43) | MAP2K7KDRTNNI3KBRAFMAPK14 | |
| SCHEMBL5449168 | 0.85 | MAP2K7 (0.42) | MAP2K7KDRTNNI3KBRAFMAPK14 | |
| SCHEMBL5323559 | 0.82 | MAP2K7 (0.43) | MAP2K7KDRTNNI3KBRAFMAPK14 | |
| SCHEMBL5435146 | 0.82 | MAP2K7 (0.45) | MAP2K7KDRTNNI3KBRAFMAPK14 | |
| SCHEMBL14447622 | 0.81 | MAP2K7 (0.46) | MAP2K7KDRTNNI3KBRAFMAPK14 | |
| SCHEMBL5335395 | 0.80 | MAP2K7 (0.43) | MAP2K7KDRTNNI3KBRAFMAPK14 | |
| SCHEMBL5445955 | 0.80 | MAP2K7 (0.44) | MAP2K7KDRTNNI3KBRAFMAPK14 | |
| SCHEMBL14447587 | 0.80 | MAP2K7 (0.54) | MAP2K7KDRTNNI3KBRAFMAPK14 | |
| SCHEMBL5332722 | 0.80 | MAP2K7 (0.43) | MAP2K7KDRTNNI3KBRAFMAPK14 | |
| SCHEMBL5334518 | 0.80 | KDR (0.61) | KDRBRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007076473-A2 | SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES | KALYPSYS, INC. (US) | 2007-07-05 | — | — | WO | disclosed |
| US-20070155764-A1 | NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES | KALYPSYS, INC. (US) | 2007-07-05 | — | — | US | disclosed |
| US-20070155764-A1 | NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES | KALYPSYS, INC. (US) | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155764-A1 | NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES | BRAF, ARAF, RAF1 | MAP2K7 141/4885KDR 555/4885TNNI3K 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.